Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | unknown | Phase 1 / Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06403709 | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | unknown | Phase 2 | 35 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06341309 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06543836 | ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06516445 | SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | unknown | Phase 2 | 33 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06495853 | Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications | unknown | Phase 2 | 208 | ZHI-ZHONG PANOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT04715633 | PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485713 | Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC | unknown | Phase 2 | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03867799 | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | unknown | Phase 2 | 25 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06415851 | Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | unknown | Phase 2 | 36 | Zhangfa SongOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05965817 | Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN(FOCUS GREEN) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06394128 | Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess | unknown | Phase 2 | 48 | First People's Hospital of HangzhouOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06206096 | PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | unknown | Phase 2 | 40 | Chinese PLA General HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06014372 | Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | unknown | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363552 | A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer | unknown | Phase 2 | 36 | Tianshu LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04543695 | A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | unknown | Phase 2 | 255 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06304987 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | unknown | Phase 2 | 50 | Beijing Friendship HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT03951337 | 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) | unknown | Phase 2 | 70 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06280690 | SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia(SGM-T1) | unknown | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | unknown | Phase 2 | 14 | Academic and Community Cancer Research UnitedOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05980689 | Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05933980 | Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer(REGOTORICOX) | unknown | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | unknown | Phase 2 / Phase 3 | 1,194 | Alliance for Clinical Trials in OncologyOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT05291156 | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | unknown | Phase 2 | 173 | University of Campania Luigi VanvitelliOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03503630 | Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma | unknown | Phase 2 | 44 | Ali ShamseddineOTHER | 2 | Jan 31, 2024 | clinicaltrials |
| NCT06231017 | Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05435313 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | unknown | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05432934 | Transversus Abdominis Plane Blocks With and Without Dexamethasone(TAP-DEX) | unknown | Phase 1 / Phase 2 | 60 | University of SaskatchewanOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05578287 | RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer(DETECT) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06134765 | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | unknown | Phase 2 | 89 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05839470 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04034459 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC(AIO-KRK-0116) | unknown | Phase 2 | 109 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 14, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 4, 2025source: clinicaltrials